Research
What Is Dihexa? The Cognitive Peptide Explained
Dihexa is one of the most hyped compounds in the nootropic world, often promoted for memory and brain health. But how much do we actually know about it? Here’s a simple guide to what Dihexa is, how it’s thought to work, and what the research really shows.
Reviewed for accuracy · Last reviewed October 17, 2026
What Is Dihexa?
Dihexa is a small synthetic compound developed at Washington State University. It’s based on angiotensin IV, a natural peptide fragment linked to learning and memory.
Its chemical name is N-hexanoic-Tyr-Ile-(6) aminohexanoic amide.
Researchers designed Dihexa to be:
- Orally active (it can work when taken by mouth in animal studies)
- Able to cross the blood-brain barrier
- Metabolically stable, meaning it breaks down slowly
How Is Dihexa Thought to Work?
Building New Brain Connections
In lab and animal studies, Dihexa was linked to synaptogenesis, the formation of new connections between brain cells. Researchers also reported more dendritic branching and dendritic spines, the structures neurons use to communicate.
The HGF/c-Met Pathway
Researchers proposed that Dihexa works by boosting hepatocyte growth factor (HGF) and its receptor, c-Met. This pathway helps support cell growth and repair, including in the brain.
What Does the Research Show?
Animal Studies
A 2013 study in the Journal of Pharmacology and Experimental Therapeutics reported that Dihexa showed strong anti-dementia activity in two rat models:
| Model | What It Tests |
|---|---|
| Scopolamine model | Memory problems caused by a drug that blocks a key memory chemical |
| Aged rat model | Memory decline linked to aging |
In both, Dihexa improved cognition. Studies also found Dihexa can cross the blood-brain barrier and build up in the brain.
Human Research
There are no published human studies of Dihexa. All current evidence comes from animal and lab research.
What About Related Compounds?
A related HGF-modulating compound from the same line of research, fosgonimeton, was tested in people with Alzheimer’s disease. In a 312-person Phase 2/3 trial (LIFT-AD), it failed to meet its main goals for improving cognition and function compared with placebo.
This doesn’t directly test Dihexa, but it shows that promising animal results in this pathway haven’t yet translated into proven benefits in humans.
Concerns About Dihexa
Theoretical Cancer Risk
The HGF/c-Met pathway that Dihexa is thought to activate also plays a role in tumor growth. Experts have noted that activating this pathway could, in theory, promote cancer. This hasn’t been studied in humans.
Research Integrity Questions
Research tied to this line of compounds has faced controversy. In 2021, reports emerged that images used in related research by a former leader of the company developing fosgonimeton had been altered. This has raised questions about parts of the evidence base.
Unknown Safety
Because there are no human studies, Dihexa’s side effects, safe dose, and long-term effects in people are unknown.
Dihexa at a Glance
| Type | Synthetic angiotensin IV analog |
|---|---|
| Developed at | Washington State University |
| Proposed target | HGF/c-Met pathway |
| Main research area | Memory and cognition |
| Human studies | None published |
| FDA-approved | No |
FAQ
- What is Dihexa? A synthetic compound based on angiotensin IV, studied in animals for memory and brain cell connections.
- What is Dihexa used for? It’s researched as a possible cognitive enhancer and for dementia, but only in animals so far.
- Does Dihexa work in humans? There are no published human studies, so it’s unknown.
- Is Dihexa safe? Its safety in humans hasn’t been studied. Experts have raised a theoretical cancer concern because of the pathway it affects.
- Is Dihexa FDA-approved? No. It’s not approved for any use.
- Is Dihexa a peptide? It’s a peptide-like compound (peptidomimetic) derived from the angiotensin IV peptide.
Key Takeaways
- Dihexa is a synthetic compound based on angiotensin IV.
- Animal studies show improved memory and more brain cell connections.
- There are no published human studies of Dihexa.
- A related compound failed a large Alzheimer’s trial in 2024.
- Its HGF/c-Met target raises a theoretical cancer concern.
Sources
- PMC – McCoy et al. (2013). Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents. Journal of Pharmacology and Experimental Therapeutics
- Alzheimer’s Drug Discovery Foundation – Cognitive Vitality Report: Dihexa
- SEC Filing – Athira Pharma Announces Topline Results From Phase 2/3 LIFT-AD Trial (2024)
- Alzheimer Europe – Athira Pharma Announces Results From Phase 2/3 LIFT-AD Trial
- Pharmaceutical Technology – Athira’s Stock Topples After Alzheimer’s Drug Flops in Phase II/III Trial
MLCR SCTY provides educational information, not medical or legal advice. Research-use-only products are not intended for human consumption.